Categories
Change Password!
Reset Password!
A single intraoperative dose of ketorolac can help patients recover faster with less opioid dependence after breast surgery.
In accordance with the findings of a double-blinded randomized controlled trial, intraoperative ketorolac improves pain control and helps patients wean off opioids sooner after breast reconstruction and reduction surgery. The study, which included 63 adult patients, compared the effects of ketorolac on postoperative opioid consumption, pain resolution, and hematoma formation.
This prospective trial randomized patients (aged 18-64 years) undergoing breast surgery into 3 groups:
Patients' opioid usage in the postoperative anesthesia care unit (PACU) and their daily opioid consumption and pain scores were monitored through patient surveys for up to 14 days postoperatively. Additionally, researchers assessed patients for postoperative hematomas both before discharge and at follow-up visits.
Key findings:
These findings suggest that a single intraoperative dose of ketorolac can offer efficient pain relief and promote opioid discontinuation in those undergoing breast surgery. However, while 30 mg ketorolac was superior in pain resolution, the 15 mg dose appeared to help patients discontinue opioids faster. As opioid reliance reduction remains a critical goal in surgical recovery, ketorolac could serve as a safe and efficient non-opioid alternative.
Plastic and Reconstructive Surgery – Global Open
Effectiveness of Intraoperative Ketorolac in Outpatient Breast Surgery: A Double-blinded Prospective Randomized Controlled Trial
Joowon M Choi et al.
Comments (0)